Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients
Synthetic phosphoethanolamine is a primary amine which has a critical role in the biosynthesis of cell membranes. Pre-clinical models have shown potential anticancer activity.
Solid Tumor
DRUG: Phosphoethanolamine
RECIST v 1.1 response rate or specific criteria for prostate cancer, 8 weeks
Treatment related toxicities as determined by CTCAE version 4.0, Every cycle, up to 30 days after drug interruption|Overall survival, Survival followed every 2 months from inclusion until death, withdrawal, loss to follow-up, or study end for up to 60 months|Disease free survival, Tumor assessment by RECIST v1.1 or prostate cancer specific criteria every 8 weeks for up to 12 months, then every 12 weeks until loss of clinical benefit, withdrawal, death, or study end for up to 24 months
Phase II multi-cohort study based on two-stage Simon design. The primary goal of the study is response rate at 8 weeks in participants with advanced solid tumors treated with synthetic phosphoethanolamine, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) or specific criteria for prostate cancer.